Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yifeijisheng is a Traditional Chinese Medicine (TCM) formulation developed by Henan University of Chinese Medicine, specifically designed for the treatment of chronic obstructive pulmonary disease (COPD). It is primarily indicated for patients in the stable phase of COPD who exhibit the TCM syndrome of Qi and Yin deficiency. The formulation is typically prepared as granules and is intended to improve respiratory function, reduce the frequency of acute exacerbations, and enhance the overall quality of life and exercise tolerance of patients. Its pharmacological action is characterized by the modulation of systemic and airway inflammation, potentially through the inhibition of pro-inflammatory cytokines and the regulation of immune responses. It is often utilized as part of an integrated Chinese and Western medicine approach to long-term COPD management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yifeijisheng.